 |
|
|
  |
|
 |
|
| |
| Color-enhanced scanning electron micrograph of thrombi occluding an artery (mag.1600x) |
| |
 |
|
Acute Care™ mass CK-MB – The Old Standard
A commonly used laboratory test to confirm the existence of myocardial damage is the measurement of a small fraction of the creatine kinase (CK) enzyme, mass CK-MB (mCK-MB). mCK-MB will not normally be elevated until 6 to 8 hours after the onset of MI.1
|
Because CK-MB can also be released from skeletal muscle, it is not specific to the myocardium. It is not uncommon for noncardiac patients to have measurable CK-MB concentrations resulting from skeletal muscle release.
While less cardiac specific than cTnI, mass CK-MB can complement a positive cTnI result to help clarify the timing of an MI.2 Reinfarction is clinically important because it is associated with incremental risk; however, it presents special diagnostic difficulties. Because increases of cTnI can be long lasting, the use of CK-MB may help clarify the timing of the reinfarction.2,3
To see how the CK-MB results on the Stratus® CS System correlate with those on Dimension® Systems, click here.
Technical Bulletins and Package Inserts for this product are available to Siemens Healthcare Diagnostics customers who are registered users of the Siemens Corporate Internet Site. To visit the site, click here.
Stratus® CS System
Acute Care™ Cardiac Troponin I
Acute Care™ Myoglobin
Acute Care™ CK-MB (mass)
Acute Care™ ßhCG
Acute Care™ D-Dimer
Acute Care™ NT-proBNP
Correlation
Connectivity
For an illustration of temporal patterns of cardiac markers after an MI, click here.
* In development.
References |
|
|
 |
 |
 |
|
|
